Equity Details
Price & Market Data
Price: $4.24
Daily Change: -$0.09 / 2.12%
Daily Range: $4.23 - $4.44
Market Cap: $248,947,008
Daily Volume: 183,775
Performance Metrics
1 Week: -8.62%
1 Month: -9.59%
3 Months: -22.20%
6 Months: -2.75%
1 Year: -4.29%
YTD: -21.48%
About Foghorn Therapeutics Inc. (FHTX)
Stock insights for Foghorn Therapeutics Inc. (FHTX). Price: 4.24, daily change: -$0.09 / 2.12%. Market cap: 248,947,008. Performance 3-month, 6-month, 1-year.
Company Details
Employees: 106
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.